Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

ABSTRACT: The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 （a PD-L1/CTLA-4 targeted bispecific antibody）.

DISEASE(S): Her2-positive Colorectal Cancer,Biliary Tract Neoplasms,Colorectal Neoplasms,Her2-positive Biliary Tract Cancer

PROVIDER: 70605 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Effect of HER2 Inhibitors on Gene Expression in Biliary Tract Cancer

Project description:HER2 is a frequently overexpressed gene in biliary tract cancer (BTC). Although several targeted agents, including trastuzumab, have been approved for the treatment of BTC, their clinical efficacy remains limited. To explore this issue, we treated two BTC cell lines—SNU1196 and GBC-SD—with different anti-HER2 agents. We then performed gene expression profiling analysis using data from RNA-seq of 2 different cells treated with different drugs.

2026-06-01 | GSE315906 | GEO

Effect of HER2 Inhibitors on Gene Expression in Biliary Tract Cancer

Project description:Effect of HER2 Inhibitors on Gene Expression in Biliary Tract Cancer

| PRJNA1399903 | ENA

Differences in the biliary microbiome between biliary tract cancer and benign biliary disease

Project description:The objective of this study is to investigate the compositional differences in the bile microbiota between malignant (BTC) and benign biliary conditions, in order to gain new insights into the pathogenesis of biliary tract cancer.

2025-08-30 | E-MTAB-15494 | biostudies-arrayexpress

MicroRNA markers for the diagnosis of pancreatic and biliary tract cancers

Project description:MicroRNAs from serum samples could detect pancreatic and biliary tract cancer patients more accurately than other traditional markers. Prospective miRNA markers for pancreatic/biliary tract cancer were selected in the training cohort. Using these miRNAs, discriminant analysis was performed, and the diagnostic accuracy, sensitivity and specificity were calculated in the test cohort.

2015-03-01 | E-GEOD-59856 | biostudies-arrayexpress

Sphere cultured biliary tract cancer cell lines SNU245 and SNU1196

Project description:We analyzed sphere cultured biliary tract cancer cell lines and analysed cancer stem cells asociated-differentially expressed genes by microarray analysis. biliary tract cancer stem cells(CSCs) associated DEG

2024-03-27 | GSE233893 | GEO

Differences in the biliary microbiome between biliary tract cancer and benign biliary disease

Project description:Differences in the biliary microbiome between biliary tract cancer and benign biliary disease

| PRJEB96013 | ENA

Zanidatamab in Patients with Early Stage HER2-positive Breast Cancer: The NeoZanHER Phase 2 Single-Arm Open-Label Trial

Project description:Strategies are needed to avoid chemotherapy in early stage HER2-positive (HER2+) breast cancer (BC). We conducted a neoadjuvant therapy trial with zanidatamab, a dual HER2-directed bispecific antibody, in patients with 1-3 cm, node-negative HER2+ BC. Primary endpoint was pathologic complete response (pCR). Secondary endpoints were radiographic response by ultrasound and magnetic resonance imaging. US and MRI, pathologic response by residual cancer burden (RCB), rate of adverse events, feasibility of accrual and biomarkers of response. Fifteen patients with HER2 IHC 3+, and 5 with HER2 IHC 2+/ISH+ BC were enrolled. Patients received zanidatamab 20 mg/kg every 2 weeks for 6 (n=11) or 10 doses (n=9). Fourteen patients also received endocrine therapy. At 6 weeks, there was a significant decrease in tumor size and volume. At surgery, six patients (30%) had pCR, meeting the prespecified pCR target, and four had limited RCB (RCB-1; 20%). Treatment was well tolerated. All patients with pCR had HER2 IHC 3+ tumors, ERBB2 amplification on WES, PAM50 HER2-high subtype, and a trend towards higher HER2 mRNA expression (p=0.06). In conclusion, de-escalation to HER2-targeted therapy alone may be feasible. Further research is needed to refine patient selection.

2026-06-23 | GSE336193 | GEO

Project description:Tumour and adjacent components from human resected biliary tract cancers were characterised for the expression of immunorelated transcripts

2018-02-14 | GSE90698 | GEO

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Project description:This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).

| 2303997 | ecrin-mdr-crc

Project description:Adjacent components from human resected biliary tract cancers were characterised for the expression of immunorelated transcripts

2018-02-14 | GSE90699 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data